DE602005001576D1 - Pyrrolidin- und thiazolidin-Derivate, deren Darstellung und Anwendung zur Behandlung von Hyperglykämie und Typ II Diabetes - Google Patents

Pyrrolidin- und thiazolidin-Derivate, deren Darstellung und Anwendung zur Behandlung von Hyperglykämie und Typ II Diabetes

Info

Publication number
DE602005001576D1
DE602005001576D1 DE602005001576T DE602005001576T DE602005001576D1 DE 602005001576 D1 DE602005001576 D1 DE 602005001576D1 DE 602005001576 T DE602005001576 T DE 602005001576T DE 602005001576 T DE602005001576 T DE 602005001576T DE 602005001576 D1 DE602005001576 D1 DE 602005001576D1
Authority
DE
Germany
Prior art keywords
hyperglycemia
pyrrolidine
diabetes
presentation
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005001576T
Other languages
English (en)
Other versions
DE602005001576T2 (de
Inventor
Nanteuil Guillaume De
Alain Benoist
Murielle Combettes
Elizabeth Harley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Publication of DE602005001576D1 publication Critical patent/DE602005001576D1/de
Application granted granted Critical
Publication of DE602005001576T2 publication Critical patent/DE602005001576T2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
DE602005001576T 2004-05-19 2005-05-18 Pyrrolidin- und Thiazolidin-Derivate, deren Darstellung und Anwendung zur Behandlung von Hyperglykämie und Typ II Diabetes Active DE602005001576T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0405454 2004-05-19
FR0405454A FR2870538B1 (fr) 2004-05-19 2004-05-19 Nouveaux derives de pyrrolidines et de thiazolidines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
DE602005001576D1 true DE602005001576D1 (de) 2007-08-23
DE602005001576T2 DE602005001576T2 (de) 2008-04-17

Family

ID=34942306

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005001576T Active DE602005001576T2 (de) 2004-05-19 2005-05-18 Pyrrolidin- und Thiazolidin-Derivate, deren Darstellung und Anwendung zur Behandlung von Hyperglykämie und Typ II Diabetes

Country Status (29)

Country Link
US (1) US7439263B2 (de)
EP (1) EP1598350B1 (de)
JP (1) JP4335171B2 (de)
KR (1) KR100747967B1 (de)
CN (1) CN100381438C (de)
AR (1) AR049278A1 (de)
AT (1) ATE366731T1 (de)
AU (1) AU2005202180B2 (de)
BR (1) BRPI0501769A (de)
CA (1) CA2506491C (de)
CY (1) CY1106878T1 (de)
DE (1) DE602005001576T2 (de)
DK (1) DK1598350T3 (de)
EA (1) EA009292B1 (de)
ES (1) ES2290864T3 (de)
FR (1) FR2870538B1 (de)
GE (1) GEP20074103B (de)
HK (1) HK1086259A1 (de)
HR (1) HRP20070376T3 (de)
MX (1) MXPA05005256A (de)
MY (1) MY139481A (de)
NO (1) NO330294B1 (de)
NZ (1) NZ540108A (de)
PL (1) PL1598350T3 (de)
PT (1) PT1598350E (de)
RS (1) RS50526B (de)
SG (1) SG117551A1 (de)
SI (1) SI1598350T1 (de)
ZA (1) ZA200504050B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2020413A1 (de) 2007-08-02 2009-02-04 Bayer CropScience AG Oxaspirocyclische-spiro-substituierte Tetram- und Tetronsäure-Derivate
GB2465132B (en) * 2007-09-21 2012-06-06 Lupin Ltd Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
RU2487866C2 (ru) * 2008-01-23 2013-07-20 Цзянсу Хэнсох Фармасьютикал Ко., Лтд. Производные дициклоазаалкана, способы их получения и их применение в медицине
WO2010146597A1 (en) 2009-06-18 2010-12-23 Lupin Limited 2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent dpp-iv inhibitors
US8440710B2 (en) * 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
CN103508931B (zh) 2012-06-25 2016-03-02 广东东阳光药业有限公司 六氢并环戊二烯衍生物、其制备方法及其在医药上的应用
KR102449196B1 (ko) 2016-01-15 2022-09-29 삼성전자주식회사 비휘발성 메모리 장치 및 비휘발성 메모리 장치의 프로그램 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0618957B2 (ja) * 1988-01-26 1994-03-16 日本合成化学工業株式会社 成形物の製造方法
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
DE4222459C2 (de) * 1992-07-08 1995-09-14 Sigma Tau Ind Farmaceuti 3,9-disubstituierte-Spiro[5.5]undecane, ein Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die diese enthalten
US5981567A (en) * 1993-07-02 1999-11-09 Bayer Aktiengesellschaft Substituted spiroheterocyclic 1h-3-aryl-pyrrolidine-2,4-dione derivatives and their use as pesticides
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6110949A (en) * 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW583185B (en) * 2000-06-13 2004-04-11 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
ES2311534T3 (es) * 2000-08-10 2009-02-16 Mitsubishi Tanabe Pharma Corporation Derivados de prolina y su uso como farmacos.
ES2271071T3 (es) * 2000-09-25 2007-04-16 Toray Industries, Inc. Compuestos espiro e inhibidores de moleculas de adherencia que contienen dichos compuestos como ingrediente activo.
FR2824825B1 (fr) * 2001-05-15 2005-05-06 Servier Lab Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2003057144A2 (en) * 2001-12-26 2003-07-17 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
HUP0200849A2 (hu) * 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
CN1633420A (zh) * 2002-04-08 2005-06-29 托伦脱药品有限公司 噻唑烷－4－腈和类似物以及它们作为二肽基－肽酶抑制剂的用途
TW200404796A (en) * 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
US7262207B2 (en) * 2002-09-19 2007-08-28 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
AU2003290577B2 (en) * 2002-11-07 2008-12-11 Merck Sharp & Dohme Corp. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes

Also Published As

Publication number Publication date
RS50526B (sr) 2010-05-07
PL1598350T3 (pl) 2007-10-31
NO20052414L (no) 2005-11-21
ATE366731T1 (de) 2007-08-15
CA2506491A1 (fr) 2005-11-19
EA009292B1 (ru) 2007-12-28
JP4335171B2 (ja) 2009-09-30
JP2005350456A (ja) 2005-12-22
US7439263B2 (en) 2008-10-21
US20050261501A1 (en) 2005-11-24
GEP20074103B (en) 2007-05-10
EP1598350B1 (de) 2007-07-11
NO20052414D0 (no) 2005-05-19
ZA200504050B (en) 2006-07-26
DE602005001576T2 (de) 2008-04-17
PT1598350E (pt) 2007-10-04
SI1598350T1 (sl) 2007-10-31
ES2290864T3 (es) 2008-02-16
MXPA05005256A (es) 2005-11-24
EA200500683A1 (ru) 2005-12-29
DK1598350T3 (da) 2007-11-12
CY1106878T1 (el) 2012-09-26
NO330294B1 (no) 2011-03-21
SG117551A1 (en) 2005-12-29
FR2870538A1 (fr) 2005-11-25
EP1598350A1 (de) 2005-11-23
HK1086259A1 (en) 2006-09-15
AR049278A1 (es) 2006-07-12
AU2005202180A1 (en) 2005-12-08
CN100381438C (zh) 2008-04-16
CN1721417A (zh) 2006-01-18
AU2005202180B2 (en) 2010-10-28
BRPI0501769A (pt) 2006-01-10
CA2506491C (fr) 2009-09-01
FR2870538B1 (fr) 2006-07-14
KR100747967B1 (ko) 2007-08-08
HRP20070376T3 (en) 2007-12-31
KR20060048007A (ko) 2006-05-18
MY139481A (en) 2009-10-30
NZ540108A (en) 2006-04-28

Similar Documents

Publication Publication Date Title
DE602005001576D1 (de) Pyrrolidin- und thiazolidin-Derivate, deren Darstellung und Anwendung zur Behandlung von Hyperglykämie und Typ II Diabetes
ATE395342T1 (de) 2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung
DE602005002470D1 (de) 1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
ATE486597T1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
DE602005017895D1 (de) Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
DE602007004119D1 (de) N-(aminoheteroaryl)-1h-indol-2-carboxamid-derivate sowie deren herstellung und therapeutische anwendung
ATE461930T1 (de) Harnstoffderivate von tropan, ihre herstellung und ihre therapeutische anwendung
DK1687049T3 (da) Sprøjter, sprøjtegrænseflader og sprøjtestempler til anvendelse med medicinske injektorer
ATE504595T1 (de) Il-22 zur behandlung von fettleibigkeit, diabetes,hyperlipidämie, hyperglykämie und insulinresistenz
DE602004022946D1 (de) 4-cyanopyrazol-3-carbonsäureamidderivate, herstellung und therapeutische anwendung davon
DE602005021501D1 (de) Sulfonamidderivate, ihre herstellung und ihre therapeutische anwendung
DE502005002056D1 (de) Neue fluorglykosidderivate von pyrazolen, diese verbindungen enthaltende arzneimittel und deren verwendung
ATE512970T1 (de) Dimere von artemisininderivaten, deren herstellung und deren therapeutische verwendung
DE502005006424D1 (de) Neue alkyl-haltige 5-acylindolinone, deren herstellung und deren verwendung als arzneimittel
BRPI0607198A2 (pt) composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica
DE602005011450D1 (de) N-(1 h-indolyl)-1 h- indol-2-carboxamid-derivate, deren herstellung und therapeutische verwendung damit
DE602005021865D1 (de) Hologramm-farbfilter, herstellungsverfahren dafür und farb-flüssigkristallanzeige damit
DE602006020713D1 (de) Alkyl-, alkenyl- und alkynylcarbamat-derivate, deren herstellung und therapeutische verwendung
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
DE602006005246D1 (de) Pyridoä2,3-düpyrimidin-derivate sowie deren herstellung und therapeutische anwendung
DE602004017463D1 (de) Diphenylpyridinderivate, deren herstellung und deren therapeutische anwendung
ATE417846T1 (de) Aminotropanderivate, deren herstellung und deren therapeutische verwendung
EP1900813A4 (de) Nesfatin, eine neue physiologische substanz, substanz in verbindung damit sowie verwendung der substanzen
DE60305037D1 (de) Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung
ATE468849T1 (de) Idebenon zur behandlung von muskeldystrophien

Legal Events

Date Code Title Description
8364 No opposition during term of opposition